Direct Biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced that the FDA cleared the company to proceed with a Phase 3 clinical trial using the investigational EV drug ExoFlo to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19.
Child vaccination rates in the United States fell during the COVID-19 pandemic as many children skipped doctors appointments and states eased vaccine requirements during remote learning, according to a government study released on April 21.
Arcturus Therapeutics announced positive Phase III trial results for the company’s mRNA vaccine candidate ARCT-154, which is intended to prevent COVID-19 caused by the SARS-CoV-2 virus.
The U.S.Food and Drug Administration granted Emergency Use Authorization (EUA) for a breathalyzer that can detect COVID-19 within three minutes.
A fourth dose of the COVID-19 vaccine from Pfizer and BioNTech provided significant added protection against severe disease, hospitalization and death for at least a month in older individuals, according to a study from Israel conducted when the Omicron variant was dominant. Additionally, new findings suggest patients with COVID-19 may have an increased risk of rare vision-threatening blood clots in the eye for months afterward.
A third dose of the COVID-19 vaccine from Pfizer (PFE.N) and BioNTech (22UAy.DE) produced significant protection against the Omicron variant of the coronavirus in healthy children ages 5 to 11, the companies said on April 14.
ReutersThe Biden administration faces an April 18 deadline on whether to extend or end a mandate requiring travelers to wear masks on airplanes, trains and in transit hubs.
ReutersThe global vaccine alliance Gavi has secured $4.8 billion in funding pledges for the vaccine-sharing scheme COVAX, an official said on Friday, falling just shy of its target.
Building on the success of its COVID-19 mRNA vaccine, Moderna, Inc. is partnering with the nonprofit scientific research organization IAVI to develop treatments and vaccines against global health threats.
The world’s first “human challenge” trial in which volunteers were deliberately exposed to the coronavirus has found that symptoms had no effect on how likely an infected person is to pass the disease on to others.